Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the companies’ supplemental New Drug Application for XTANDI® for the treatment of patients with non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
